Aevi Genomic Medicine is a clinical stage biopharmaceutical company with a focus on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated therapies for pediatric onset, life-altering diseases, including rare and orphan diseases. Co.'s product pipeline includes: AEVI-002, which is an anti-LIGHT monoclonal antibody that is in development for use in Pediatric Onset Crohn's disease; and AEVI-005, which is the monoclonal antibody Co. is developing as part of its ongoing collaboration with Kyowa Hakko Kirin Co., Ltd. whereby Co. is studying it in an undisclosed ultra-orphan auto-immune pediatric disease. We show 37 historical shares outstanding datapoints in our GNMX shares outstanding history coverage, used to compute GNMX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GNMX market cap history over the course of time is important for investors
interested in comparing GNMX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GNMX versus a peer is one thing; comparing
GNMX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GNMX can fluctuate over the course of history.
With this page we aim to empower investors researching GNMX by allowing them to research the GNMX market cap history. |
Free GNMX Email Alerts:
Video: The Importance of Market Cap
